Are you a JL Aesthetics VIP Member?

JOIN NOW
banner

DAXXIFY

DAXXIFY

The first and only peptide-powered, FDA-approved frown line treatment designed to minimize the appearance of facial wrinkles, creating more competition in a market that has long been dominated by Botox.

With a median duration of 6 months and up to 9 months for some patients.

Frequently Asked Questions

What Is Daxxify?

Daxxify was developed by the manufacturer Revance Therapeutics. Studies showed the drug can temporarily improve “moderate to severe frown lines” in adults for a median duration of six months, which is up to two months longer than the period generally provided by Botox.

How Does It Work?

Like Botox, Daxxify is an acetylcholine release inhibitor and neuromuscular blocking agent. This means blocking certain chemical signals from nerves, mostly signals that cause muscles to contract, and temporarily relaxing the facial muscles that cause wrinkles.

The injection can also used to treat conditions such as neck spasms, excessive sweating, an overactive bladder, and lazy eye.

Daxxify was found to be “generally safe and well tolerated” with no serious treatment-related adverse events reported in during the clinical trials.

WARNING: DISTANT SPREAD OF TOXIN EFFECT

The effects of DAXXIFY™ and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY™ is not approved for the treatment of spasticity or any conditions other than glabellar lines.

Indication

DAXXIFY™ (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

Important Safety Information

DAXXIFY™ contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency Units of DAXXIFY™ are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Co-administration of DAXXIFY™ and aminoglycoside antibiotics, anticholinergic agents or any other agents interferinCo-administration of DAXXIFY™ and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY™ may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY™ is unknown.

DAXXIFY™ is not recommended for use in children or pregnant women.

Please see DAXXIFY™ full Prescribing Information, including Boxed Warning and Medication Guide.

  • DAXXIFY™. Prescribing Information. Revance Therapeutics, Inc, 2022.
  • Fabi SG, Cohen JL, Green LJ, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study. Dermatol Surg. 2021;47(1):48-54.
  • BOTOX® Cosmetic. Prescribing Information. Allergan Inc; 2020.
  • XEOMIN®. Prescribing Information. Merz Pharmaceuticals GmbH; 2021.
  • DYSPORT®. Prescribing Information. Ipsen Biopharm Ltd; 2020.
  • JEUVEAU®. Prescribing Information. Evolus, Inc; 2020.
  • Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145(1):45-58.
  • Data on File. Protocols 1620301-303. Post Hoc Analysis. Newark, CA: Revance Therapeutics, Inc, 2021.
  • Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). J Am Acad Dermatol. 2020;82(4):838-845.